RxDoctor Payments Data

Teresa Fu, MD

Dermatology · Palo Alto, CANPI 1164716619

Payments from drug & device makers

$4,293in general payments, 2019–2025

Across 176 payments — averaging $24.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$584
  • Arcutis Biotherapeutics, Inc.$568
  • AbbVie$449
  • Regeneron Healthcare Solutions, Inc.$419
  • Amgen$349
  • Incyte Corporation$313
  • plus $2K from 12 others

What the payments were for

  • Food & beverage$4,17097%
  • Education$1223%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,293 in reported general payments places this provider in the 65th percentile of 1,875 dermatology providers in California.

See all dermatology providers in California

Medicare billing

Part B allowed, 2024
$212,936
Medicare patients
561
Services billed
2,890

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OtezlaApremilast18$86,416
RinvoqUpadacitinib11$68,925
Tacrolimus28$3,086
Clobetasol Propionate42$1,760
Fluocinonide44$1,654
Fluorouracil23$1,351
Triamcinolone Acetonide110$1,227
Ketoconazole66$858
Doxycycline Hyclate21$447
Mometasone Furoate16$425
ValacyclovirValacyclovir Hcl12$390
Betamethasone Diprop AugmentedBetamethasone/Propylene Glyc37$331
CiclopiroxCiclopirox Olamine11$290
Minoxidil39$238
Clindamycin Phosphate12$237

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AmgenOtezla$349$86,41618 claims
AbbVieRinvoq$449$68,92511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,875 dermatology providers in California.

Other dermatology in Palo Alto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →